( February 19, 2026, 2:32 PM EST) -- WASHINGTON, D.C. — In its Feb. 18 merits brief before the U.S. Supreme Court, a bioequivalent pharmaceutical maker argues that a patent holder’s complaint failed to state a claim for induced infringement because the “skinny label” generic version of the patent carved out the patented cardiovascular use of the drug....